Pfizer, Roche Looking Beyond Simple Licensing In China Deals

2026-04-07 15:34:50

Abstract generation in progress

Pfizer and Roche are reportedly moving beyond traditional licensing agreements in their dealings in the Chinese market, indicating a shift in their strategic approach. The article from Scrip highlights this change in strategy. The information was presented at the BIO CHINA conference in 2026.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes